Form 4: Thermo Fisher Director Defers Compensation into Stock Units

Jennifer M. Johnson, a director at Thermo Fisher Scientific, acquired 66.02 phantom stock units through a deferred compensation plan.

Summary

• Jennifer M. Johnson, a Director of Thermo Fisher Scientific Inc. (TMO), acquired 66.02 phantom stock units.
• The transaction occurred on March 28, 2026, at a price of $473.36 per unit.
• These units were credited to her account under the Issuer's Deferred Compensation Plan for Directors.
• Directors' retainers are deferred quarterly into Common Stock units based on the closing stock price at quarter-end.
• The phantom stock units are convertible into Common Stock on a 1-for-1 basis.
• Shares will be distributed upon cessation of director service (for any reason) or a change of control.
• Following this transaction, Ms. Johnson beneficially owns 661.31 phantom stock units.
• Ms. Johnson is also the President, CEO, and a Director of Franklin Resources, Inc. (Franklin Templeton), and disclaims beneficial ownership of TMO securities held by Franklin Templeton subsidiaries.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine compensation practices and a minor increase in director ownership alignment, without significant operational or financial implications.

Positives

• The acquisition of phantom stock units by a director increases their alignment with shareholder interests, as their compensation is tied to the company's stock performance.

Future Outlook

The phantom stock units are distributable as common stock upon the cessation of director service or a change of control, indicating a future conversion event tied to specific conditions.

Management Comments

• Jennifer M. Johnson disclaims beneficial ownership of Thermo Fisher Scientific securities held by Franklin Templeton subsidiaries, which manage investment products and client accounts in the ordinary course of business.

Industry Context

StockSavvy.ai notes that deferred compensation plans for directors, often involving equity-based awards like phantom stock units, are a common practice across various industries, including the life sciences and diagnostics sector where Thermo Fisher Scientific operates. These plans are designed to align the interests of directors with long-term shareholder value.

Comparison to Industry Standards

• The use of phantom stock units as a component of director compensation is a standard practice among large, publicly traded companies, including peers in the S&P 500 and the healthcare technology sector.
• Companies like Danaher Corporation and Abbott Laboratories also utilize similar equity-based deferred compensation structures for their non-employee directors to foster long-term commitment and align incentives.

Corporate Governance

Related Party Transactions

• Jennifer M. Johnson is President, Chief Executive Officer and a Director of Franklin Resources, Inc. (Franklin Templeton). Franklin Templeton subsidiaries manage investment products and client accounts that hold equity securities of Thermo Fisher Scientific Inc. in the ordinary course of business. Ms. Johnson disclaims beneficial ownership of such securities.

Stakeholder Impact

• Shareholders: Increased alignment of a director's financial interests with the company's long-term stock performance.
• Directors: Compensation structure provides for deferred equity ownership, linking their financial outcomes to the company's success.

Next Steps

• The phantom stock units will convert to common stock upon the cessation of Jennifer M. Johnson's director service or a change of control at Thermo Fisher Scientific.

Key Dates

Recommendation

This Form 4 filing details a routine, non-open market transaction related to director compensation. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The increase in director ownership, while positive for alignment, is not significant enough to alter the fundamental investment thesis for Thermo Fisher Scientific.

Keywords

Thermo Fisher Scientific, TMO, Jennifer M. Johnson, Director Compensation, Phantom Stock Units, Deferred Compensation Plan, Insider Transaction, Form 4